Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AZTA 
Azenta Inc (AZTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: AZTA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $33
1 Year Target Price $33
| 1 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.33% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.38B USD | Price to earnings Ratio - | 1Y Target Price 33 |
Price to earnings Ratio - | 1Y Target Price 33 | ||
Volume (30-day avg) 7 | Beta 1.59 | 52 Weeks Range 23.91 - 55.63 | Updated Date 08/29/2025 |
52 Weeks Range 23.91 - 55.63 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate 0.13 | Actual 0.19 |
Profitability
Profit Margin -16.68% | Operating Margin (TTM) 0.03% |
Management Effectiveness
Return on Assets (TTM) -1.6% | Return on Equity (TTM) -9.15% |
Valuation
Trailing PE - | Forward PE 29.07 | Enterprise Value 1105295661 | Price to Sales(TTM) 2.07 |
Enterprise Value 1105295661 | Price to Sales(TTM) 2.07 | ||
Enterprise Value to Revenue 1.65 | Enterprise Value to EBITDA 98.14 | Shares Outstanding 45839700 | Shares Floating 40167978 |
Shares Outstanding 45839700 | Shares Floating 40167978 | ||
Percent Insiders 1.8 | Percent Institutions 116.63 |
Upturn AI SWOT
Azenta Inc
Company Overview
History and Background
Azenta, Inc. (formerly Brooks Automation) was founded in 1978. Initially focused on robotics and automation solutions, it has evolved into a life sciences company providing sample management and genomics services. Key milestones include acquisitions of companies expanding its capabilities in sample management and genomics.
Core Business Areas
- Sample Management Solutions: Offers automated storage systems, cryogenic services, and related consumables for biological samples. This includes managing and storing samples at ultra-low temperatures, retrieval, and tracking.
- Genomics Services: Provides genomic services such as DNA sequencing, gene synthesis, and other molecular biology services to accelerate research and development in the life sciences industry.
Leadership and Structure
The leadership team includes the CEO, CFO, and other executives responsible for the company's strategic direction and operational management. Azenta operates with a functional organizational structure, with divisions dedicated to sample management and genomics.
Top Products and Market Share
Key Offerings
- Automated Storage Systems: Provides automated cryogenic and -20 degree sample storage systems for biological samples. Market share estimated between 10-15%. Competitors include Thermo Fisher Scientific (TMO), BioLife Solutions (BLFS). Revenue is included in the Sample Management Solutions segment revenue.
- Gene Synthesis Services: Provides custom gene synthesis services, offering researchers synthetic DNA constructs for various applications. Market share is relatively small but growing due to research demands. Key competitors are GenScript Biotech (1548.HK), Twist Bioscience (TWST). Revenue is included in the Genomics Services segment revenue.
Market Dynamics
Industry Overview
The life sciences market is experiencing substantial growth, driven by advancements in genomics, personalized medicine, and biopharmaceutical research. Demand for sample management and genomic services is increasing due to the need for efficient data and sample handling in the drug discovery and research process.
Positioning
Azenta is positioned as a key player in providing integrated solutions for sample management and genomic services. Its competitive advantage lies in its expertise in both areas and its ability to offer comprehensive solutions.
Total Addressable Market (TAM)
The estimated TAM for sample management and genomics services is ~$20 Billion. Azenta is positioned to capture a portion of this market through its integrated solutions and global presence.
Upturn SWOT Analysis
Strengths
- Strong presence in sample management and genomics
- Diversified service offerings
- Global reach and established customer base
- Expertise in automation and robotics
Weaknesses
- Limited brand recognition compared to larger competitors
- Dependence on R&D spending in the life sciences industry
- Potential for margin pressure due to competition
- Exposure to macroeconomic fluctuations
Opportunities
- Expanding market for personalized medicine and genomics
- Increasing demand for sample storage and retrieval
- Growing partnerships with pharmaceutical companies
- Potential for strategic acquisitions
Threats
- Competition from larger, established companies
- Technological obsolescence
- Regulatory changes impacting the life sciences industry
- Economic downturn affecting R&D spending
Competitors and Market Share
Key Competitors
- TMO
- ILMN
- BLFS
- WAT
Competitive Landscape
Azenta faces competition from larger, more diversified companies with greater resources. Its focus on integrated solutions provides a competitive advantage.
Major Acquisitions
Bionexus
- Year: 2021
- Acquisition Price (USD millions): 75
- Strategic Rationale: Expanded sample management services and increased presence in biopharmaceutical markets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by acquisitions and organic expansion of services.
Future Projections: Future projections are based on growth in the genomics and sample management market. Analyst estimates vary depending on market conditions.
Recent Initiatives: Recent initiatives include expanding genomics service offerings and strengthening sample management infrastructure.
Summary
Azenta is a focused life sciences company specializing in sample management and genomics. Its strengths lie in its expertise and integrated solutions but faces competition from larger players. The company is well-positioned to benefit from the growing personalized medicine sector. Its future will depend on successfully integrating acquired entities, navigating intense competition, and maintaining pace with technological advancements.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- SEC filings
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Financial performance is subject to change based on market conditions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Azenta Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 1995-02-02 | President, CEO & Director Mr. John P. Marotta | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 3000 | Website https://www.azenta.com |
Full time employees 3000 | Website https://www.azenta.com | ||
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates through three reportable segments: Sample Management Solutions, Multiomics, and B Medical Systems. The Sample Management Solutions segment provides sample management products and solutions, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, synthesis editing, and related services. The B Medical Systems segment manufactures and distributes temperature-controlled storage and transportation solutions to governments, health institutions, and non-government organizations. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.